10547-56-5

Upstream product

• 626-62-0 Cyclohexyl iodide 
• 1007476-32-5 sodium ethyl acetylacetate enolate 
• 141-97-9 ethyl acetoacetate 
• 108-93-0 cyclohexanol 
• 7637-07-2 boron trifluoride 
• 823-76-7 Cyclohexyl methyl ketone 
• 105-58-8 Diethyl carbonate 

Downstream Products

• 111829-45-9 cyclohexyl-methyl-maleic acid-anhydride 
• 103-78-6 4-cyclohexyl-butan-2-one 
• 91950-24-2 2-cyclohexyl-4-hydroxy-acetoacetic acid-lactone 
• 5452-75-5 ethyl 2-cyclohexylacetate 
• 13275-31-5 ethyl cyclohexyloxoacetate 
• 1248346-66-8 3-cyclohexyl-2-methylquinolin-4(1H)-one 
• 34220-13-8 2-Cyclohexyl-2-buten-1-ol 
• 34220-11-6 3-cyclohexylbut-3-en-2-ol 

Relevant academic research and scientific papers

Substituted phenyl pyrazolone derivatives and preparation and application (by machine translation)

The present invention provides a substituted phenyl pyrazolone derivatives, in particular to a 2 - phenyl - pyrazoline - 3 - ketone compound and its pharmaceutically acceptable salt, solvate. The substituted acetic acid ethyl ester with sodium hydroxide in aqueous solution in the [...] reflux reaction, then in the palladium-carbon and hydrogen under the action of the hydrogenolysis benzyl, phenyl [...] obtained, with the bromochlorodifluoromethane alkane reaction to obtain the chloro, finally with the secondary amine on the condensation to obtain the target compound. The invention substituted phenyl pyrazoline compounds in vitro exhibits excellent capability of eliminating the free radicals, and have more strongly inhibit H3 receptor activity, exhibits excellent penetration of the blood brain barrier capacity, has a unique dual active, therefore, its for cerebral apoplexy, Alzheimer's disease, Parkinson's disease, progressive neurodegenerative diseases such as frozen sickness treatment has a unique clinical effect. The compound of the invention for treating central system system related disease and inflammatory disease application of the medicament. The formula structure is as follows: (by machine translation)

Endochin optimization: Structure-activity and structure-property relationship studies of 3-substituted 2-Methyl-4(1 H)-quinolones with antimalarial activity

Since the 1940s endochin and analogues thereof were known to be causal prophylactic and potent erythrocytic stage agents in avian models. Preliminary screening in a current in vitro assay identified several 4(1H)-quinolones with nanomolar EC50 against erythrocytic stages of multidrug resistant W2 and TM90-C2B isolates of Plasmodium falciparum. Follow-up structure-activity relationship (SAR) studies on 4(1H)-quinolone analogues identified several key features for biological activity. Nevertheless, structure-property relationship (SPR) studies conducted in parallel revealed that 4(1H)-quinolone analogues are limited by poor solubilities and rapid microsomal degradations. To improve the overall efficacy, multiple 4(1H)-quinolone series with varying substituents on the benzenoid quinolone ring and/or the 3-position were synthesized and tested for in vitro antimalarial activity. Several structurally diverse 6-chloro-2-methyl-7-methoxy-4(1H)-quinolones with EC50 in the low nanomolar range against the clinically relevant isolates W2 and TM90-C2B were identified with improved physicochemical properties while maintaining little to no cross-resistance with atovaquone.